1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Proteases	_	_	NNS	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	associated	_	_	VBN	_	_	_	_	_
4	with	_	_	IN	_	_	_	_	_
5	many	_	_	JJ	_	_	_	_	_
6	signaling	_	_	VBG	_	_	_	_	_
7	biological	_	_	JJ	_	_	_	_	_
8	pathways	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	it	_	_	PRP	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	has	_	_	VBZ	_	_	_	_	_
14	been	_	_	VBN	_	_	_	_	_
15	proven	_	_	VBN	_	_	_	_	_
16	that	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	number	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	diseases	_	_	NNS	_	_	_	_	_
21	like	_	_	IN	_	_	_	_	_
22	cancer	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	HIV	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	infectious	_	_	JJ	_	_	_	_	_
27	diseases	_	_	NNS	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	diabetes	_	_	NNS	_	_	_	_	_
31	are	_	_	VBP	_	_	_	_	_
32	treated	_	_	VBN	_	_	_	_	_
33	by	_	_	IN	_	_	_	_	_
34	inhibiting	_	_	VBG	_	_	_	_	_
35	proteases	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	Pharmaceutical	_	_	JJ	_	_	_	_	_
2	companies	_	_	NNS	_	_	_	_	_
3	develop	_	_	VBP	_	_	_	_	_
4	commercial	_	_	JJ	_	_	_	_	_
5	drugs	_	_	NNS	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	inhibit	_	_	VB	_	_	_	_	_
8	aspartyl	_	_	NN	_	_	_	_	_
9	proteases	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	serine	_	_	NN	_	_	_	_	_
12	proteases	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	cysteine	_	_	NN	_	_	_	_	_
16	proteases	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Among	_	_	IN	_	_	_	_	_
2	several	_	_	JJ	_	_	_	_	_
3	protease	_	_	NN	_	_	_	_	_
4	inhibitors	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	serine	_	_	NN	_	_	_	_	_
7	protease	_	_	NN	_	_	_	_	_
8	inhibitors	_	_	NNS	_	_	_	_	_
9	received	_	_	VBD	_	_	_	_	_
10	significant	_	_	JJ	_	_	_	_	_
11	interest	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	various	_	_	JJ	_	_	_	_	_
14	applications	_	_	NNS	_	_	_	_	_
15	focused	_	_	VBN	_	_	_	_	_
16	mainly	_	_	RB	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	therapeutics	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Serine	_	_	NN	_	_	_	_	_
2	protease	_	_	NN	_	_	_	_	_
3	inhibitors	_	_	NNS	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	Table	_	_	NN	_	_	_	_	_
7	1	_	_	CD	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	used	_	_	VBN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	treating	_	_	VBG	_	_	_	_	_
13	diseases	_	_	NNS	_	_	_	_	_
14	like	_	_	IN	_	_	_	_	_
15	immune-related	_	_	JJ	_	_	_	_	_
16	disorders	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	inflammatory	_	_	JJ	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	respiratory	_	_	JJ	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	AIDS	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	neurodegenerative	_	_	JJ	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	metabolic	_	_	JJ	_	_	_	_	_
28	disorders	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Features	_	_	NNS	_	_	_	_	_
2	like	_	_	IN	_	_	_	_	_
3	therapeutic	_	_	JJ	_	_	_	_	_
4	potential	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	good	_	_	JJ	_	_	_	_	_
7	binding	_	_	NN	_	_	_	_	_
8	affinity	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	low	_	_	JJ	_	_	_	_	_
11	toxicity	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	quickly	_	_	RB	_	_	_	_	_
15	cleavable	_	_	JJ	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	proteolytic	_	_	JJ	_	_	_	_	_
18	enzymes	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	make	_	_	VBP	_	_	_	_	_
21	cyclic	_	_	JJ	_	_	_	_	_
22	peptides	_	_	NNS	_	_	_	_	_
23	potential	_	_	JJ	_	_	_	_	_
24	future	_	_	JJ	_	_	_	_	_
25	therapeutics	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Most	_	_	JJS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	cyclic	_	_	JJ	_	_	_	_	_
5	peptides	_	_	NNS	_	_	_	_	_
6	approved	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	FDA	_	_	NNP	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	shown	_	_	VBN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	Table	_	_	NN	_	_	_	_	_
14	2	_	_	CD	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	are	_	_	VBP	_	_	_	_	_
17	used	_	_	VBN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	bacterial	_	_	JJ	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	fungal	_	_	JJ	_	_	_	_	_
22	infections	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	oncology	_	_	NN	_	_	_	_	_
25	drugs	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	gastrointestinal	_	_	JJ	_	_	_	_	_
28	disorders	_	_	NNS	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	anemia	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Recently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	cyclic	_	_	JJ	_	_	_	_	_
4	peptides	_	_	NNS	_	_	_	_	_
5	were	_	_	VBD	_	_	_	_	_
6	proven	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	inhibit	_	_	VB	_	_	_	_	_
9	HIV-1	_	_	NN	_	_	_	_	_
10	protease	_	_	NN	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	aspartyl	_	_	NN	_	_	_	_	_
13	proteases	_	_	NNS	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	elastase	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	shedding	_	_	VBG	_	_	_	_	_
19	light	_	_	NN	_	_	_	_	_
20	onto	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	use	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	cyclic	_	_	JJ	_	_	_	_	_
25	peptides	_	_	NNS	_	_	_	_	_
26	as	_	_	IN	_	_	_	_	_
27	protease	_	_	NN	_	_	_	_	_
28	inhibitors	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Phage	_	_	NN	_	_	_	_	_
2	display	_	_	NN	_	_	_	_	_
3	technology	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	Incretin-based	_	_	JJ	_	_	_	_	_
6	cyclic	_	_	JJ	_	_	_	_	_
7	peptide	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	cyclic	_	_	JJ	_	_	_	_	_
10	peptides	_	_	NNS	_	_	_	_	_
11	from	_	_	IN	_	_	_	_	_
12	mRNA	_	_	NN	_	_	_	_	_
13	display	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	split-pool	_	_	JJ	_	_	_	_	_
17	synthesis	_	_	NN	_	_	_	_	_
18	are	_	_	VBP	_	_	_	_	_
19	some	_	_	DT	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	tools	_	_	NNS	_	_	_	_	_
23	used	_	_	VBN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	develop	_	_	VB	_	_	_	_	_
26	cyclic	_	_	JJ	_	_	_	_	_
27	peptide	_	_	NN	_	_	_	_	_
28	compounds	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Recently	_	_	RB	_	_	_	_	_
2	computer-aided	_	_	JJ	_	_	_	_	_
3	drug	_	_	NN	_	_	_	_	_
4	design	_	_	NN	_	_	_	_	_
5	technologies	_	_	NNS	_	_	_	_	_
6	like	_	_	IN	_	_	_	_	_
7	molecular	_	_	JJ	_	_	_	_	_
8	docking	_	_	NN	_	_	_	_	_
9	simulations	_	_	NNS	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	applied	_	_	VBN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	identify	_	_	VB	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	design	_	_	NN	_	_	_	_	_
16	rationally	_	_	RB	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	called	_	_	VBN	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	de	_	_	FW	_	_	_	_	_
21	novo	_	_	FW	_	_	_	_	_
22	developed	_	_	VBN	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	develop	_	_	VB	_	_	_	_	_
27	cyclic	_	_	JJ	_	_	_	_	_
28	peptide	_	_	NN	_	_	_	_	_
29	ligand	_	_	NN	_	_	_	_	_
30	as	_	_	IN	_	_	_	_	_
31	leads	_	_	NNS	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	therapeutic	_	_	JJ	_	_	_	_	_
34	drug	_	_	NN	_	_	_	_	_
35	targets	_	_	NNS	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	interest	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Till	_	_	IN	_	_	_	_	_
2	today	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	cyclic	_	_	JJ	_	_	_	_	_
5	peptides	_	_	NNS	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	therapeutics	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	regulating	_	_	VBG	_	_	_	_	_
10	glucose	_	_	NN	_	_	_	_	_
11	metabolism	_	_	NN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	inhibiting	_	_	VBG	_	_	_	_	_
14	proteases	_	_	NNS	_	_	_	_	_
15	have	_	_	VBP	_	_	_	_	_
16	not	_	_	RB	_	_	_	_	_
17	been	_	_	VBN	_	_	_	_	_
18	reported	_	_	VBN	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	treatment	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	diabetes	_	_	NN	_	_	_	_	_
24	mellitus	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	Mexico	_	_	NNP	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	approximately	_	_	RB	_	_	_	_	_
5	11.5	_	_	CD	_	_	_	_	_
6	million	_	_	CD	_	_	_	_	_
7	people	_	_	NNS	_	_	_	_	_
8	live	_	_	VBP	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	diabetes	_	_	NN	_	_	_	_	_
11	mellitus	_	_	NN	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	DM	_	_	NN	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	which	_	_	WDT	_	_	_	_	_
17	is	_	_	VBZ	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	main	_	_	JJ	_	_	_	_	_
20	leading	_	_	VBG	_	_	_	_	_
21	cause	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	acquired	_	_	VBN	_	_	_	_	_
24	blindness	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	non-traumatic	_	_	JJ	_	_	_	_	_
27	lower-limb	_	_	JJ	_	_	_	_	_
28	amputations	_	_	NNS	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	chronic	_	_	JJ	_	_	_	_	_
32	kidney	_	_	NN	_	_	_	_	_
33	failure	_	_	NN	_	_	_	_	_
34	diseases	_	_	NNS	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Human	_	_	JJ	_	_	_	_	_
2	dipeptidyl	_	_	NN	_	_	_	_	_
3	peptidase-4	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	DPP4	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	serine	_	_	NN	_	_	_	_	_
10	protease	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	well	_	_	RB	_	_	_	_	_
13	known	_	_	VBN	_	_	_	_	_
14	FDA-approved	_	_	JJ	_	_	_	_	_
15	therapeutic	_	_	JJ	_	_	_	_	_
16	drug	_	_	NN	_	_	_	_	_
17	target	_	_	NN	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	regulating	_	_	VBG	_	_	_	_	_
20	blood	_	_	NN	_	_	_	_	_
21	glucose	_	_	NN	_	_	_	_	_
22	metabolism	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	treating	_	_	VBG	_	_	_	_	_
25	diabetes	_	_	NN	_	_	_	_	_
26	mellitus	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Sitagliptin	_	_	NNP	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	Vildagliptin	_	_	NNP	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	Anagliptin	_	_	NNP	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	Saxagliptin	_	_	NNP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	Alogliptin	_	_	NNP	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	main	_	_	JJ	_	_	_	_	_
14	clinically	_	_	RB	_	_	_	_	_
15	used	_	_	VBN	_	_	_	_	_
16	chemicals	_	_	NNS	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	human	_	_	JJ	_	_	_	_	_
19	dipeptidyl	_	_	NN	_	_	_	_	_
20	peptidase-4	_	_	NN	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	DPP4	_	_	NN	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	inhibition	_	_	NN	_	_	_	_	_
25	despite	_	_	IN	_	_	_	_	_
26	their	_	_	PRP$	_	_	_	_	_
27	side	_	_	NN	_	_	_	_	_
28	effects	_	_	NNS	_	_	_	_	_
29	as	_	_	IN	_	_	_	_	_
30	pancreatitis	_	_	NN	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	nausea	_	_	NN	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	anemia	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	well	_	_	RB	_	_	_	_	_
4	known	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	incretin	_	_	NN	_	_	_	_	_
7	hormones	_	_	NNS	_	_	_	_	_
8	glucagon-like	_	_	JJ	_	_	_	_	_
9	peptide	_	_	NN	_	_	_	_	_
10	1	_	_	CD	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	GLP-1	_	_	NN	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	glucose-dependent	_	_	JJ	_	_	_	_	_
16	insulinotropic	_	_	JJ	_	_	_	_	_
17	polypeptide	_	_	NN	_	_	_	_	_
18	(	_	_	-LRB-	_	_	_	_	_
19	GIP	_	_	NN	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	are	_	_	VBP	_	_	_	_	_
22	responsible	_	_	JJ	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	insulin	_	_	NN	_	_	_	_	_
25	release	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	glucose	_	_	NN	_	_	_	_	_
28	regulation	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	hormones	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	inactivated	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	serine	_	_	NN	_	_	_	_	_
8	protease	_	_	NN	_	_	_	_	_
9	human	_	_	JJ	_	_	_	_	_
10	dipeptidyl	_	_	NN	_	_	_	_	_
11	peptidase-4	_	_	NN	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	DPP4	_	_	NN	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Since	_	_	IN	_	_	_	_	_
2	natural	_	_	JJ	_	_	_	_	_
3	cyclic	_	_	JJ	_	_	_	_	_
4	peptides	_	_	NNS	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	proven	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	inhibit	_	_	VB	_	_	_	_	_
9	various	_	_	JJ	_	_	_	_	_
10	proteases	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	consider	_	_	VB	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	beneficial	_	_	JJ	_	_	_	_	_
17	aspects	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	cyclic	_	_	JJ	_	_	_	_	_
20	peptides	_	_	NNS	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	comparison	_	_	NN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	small	_	_	JJ	_	_	_	_	_
25	chemicals	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	like	_	_	IN	_	_	_	_	_
28	less	_	_	JJR	_	_	_	_	_
29	toxicity	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	no	_	_	DT	_	_	_	_	_
32	accumulation	_	_	NN	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	organs	_	_	NNS	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	rapid	_	_	JJ	_	_	_	_	_
38	degradation	_	_	NN	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	peptides	_	_	NNS	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	we	_	_	PRP	_	_	_	_	_
43	hypothesized	_	_	VBD	_	_	_	_	_
44	that	_	_	IN	_	_	_	_	_
45	cyclic	_	_	JJ	_	_	_	_	_
46	peptides	_	_	NNS	_	_	_	_	_
47	from	_	_	IN	_	_	_	_	_
48	natural	_	_	JJ	_	_	_	_	_
49	sources	_	_	NNS	_	_	_	_	_
50	could	_	_	MD	_	_	_	_	_
51	be	_	_	VB	_	_	_	_	_
52	an	_	_	DT	_	_	_	_	_
53	alternative	_	_	JJ	_	_	_	_	_
54	source	_	_	NN	_	_	_	_	_
55	of	_	_	IN	_	_	_	_	_
56	therapeutics	_	_	NNS	_	_	_	_	_
57	to	_	_	TO	_	_	_	_	_
58	inhibit	_	_	VB	_	_	_	_	_
59	serine	_	_	NN	_	_	_	_	_
60	protease	_	_	NN	_	_	_	_	_
61	DPP4	_	_	NN	_	_	_	_	_
62	for	_	_	IN	_	_	_	_	_
63	treatment	_	_	NN	_	_	_	_	_
64	of	_	_	IN	_	_	_	_	_
65	diabetes	_	_	NN	_	_	_	_	_
66	mellitus	_	_	NN	_	_	_	_	_
67	.	_	_	.	_	_	_	_	_


1	Among	_	_	IN	_	_	_	_	_
2	various	_	_	JJ	_	_	_	_	_
3	naturally	_	_	RB	_	_	_	_	_
4	occurring	_	_	VBG	_	_	_	_	_
5	cyclic	_	_	JJ	_	_	_	_	_
6	peptides	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	oxytocin	_	_	NN	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	natural	_	_	JJ	_	_	_	_	_
11	cyclic	_	_	JJ	_	_	_	_	_
12	peptide	_	_	NN	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	was	_	_	VBD	_	_	_	_	_
15	chosen	_	_	VBN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	this	_	_	DT	_	_	_	_	_
18	study	_	_	NN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	prove	_	_	VB	_	_	_	_	_
21	our	_	_	PRP$	_	_	_	_	_
22	hypothesis	_	_	NN	_	_	_	_	_
23	that	_	_	IN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	cyclic	_	_	JJ	_	_	_	_	_
26	peptides	_	_	NNS	_	_	_	_	_
27	possess	_	_	VBP	_	_	_	_	_
28	serine	_	_	NN	_	_	_	_	_
29	protease	_	_	NN	_	_	_	_	_
30	inhibition	_	_	NN	_	_	_	_	_
31	activity	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	specifically	_	_	RB	_	_	_	_	_
35	inhibit	_	_	VB	_	_	_	_	_
36	DPP4	_	_	NNP	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	demonstrate	_	_	VB	_	_	_	_	_
3	our	_	_	PRP$	_	_	_	_	_
4	hypothesis	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	activity	_	_	NN	_	_	_	_	_
7	atlas	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	field-based	_	_	JJ	_	_	_	_	_
10	models	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	DPP4	_	_	NN	_	_	_	_	_
13	inhibitors	_	_	NNS	_	_	_	_	_
14	from	_	_	IN	_	_	_	_	_
15	natural	_	_	JJ	_	_	_	_	_
16	origin	_	_	NN	_	_	_	_	_
17	were	_	_	VBD	_	_	_	_	_
18	utilized	_	_	VBN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	elucidate	_	_	VB	_	_	_	_	_
21	molecular	_	_	JJ	_	_	_	_	_
22	insights	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	oxytocin	_	_	NN	_	_	_	_	_
25	peptide	_	_	NN	_	_	_	_	_
26	into	_	_	IN	_	_	_	_	_
27	DPP4	_	_	NN	_	_	_	_	_
28	inhibition	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	molecular	_	_	JJ	_	_	_	_	_
5	docking	_	_	NN	_	_	_	_	_
6	simulations	_	_	NNS	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	used	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	understand	_	_	VB	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	binding	_	_	NN	_	_	_	_	_
13	poses	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	interacting	_	_	VBG	_	_	_	_	_
16	residues	_	_	NNS	_	_	_	_	_
17	responsible	_	_	JJ	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	inhibitory	_	_	JJ	_	_	_	_	_
20	activity	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Also	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	stability	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	water	_	_	NN	_	_	_	_	_
7	molecules	_	_	NNS	_	_	_	_	_
8	at	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	binding	_	_	NN	_	_	_	_	_
11	site	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	oxytocin	_	_	NN	_	_	_	_	_
14	was	_	_	VBD	_	_	_	_	_
15	studied	_	_	VBN	_	_	_	_	_
16	using	_	_	VBG	_	_	_	_	_
17	3D	_	_	JJ	_	_	_	_	_
18	reference	_	_	NN	_	_	_	_	_
19	interaction	_	_	NN	_	_	_	_	_
20	site	_	_	NN	_	_	_	_	_
21	model	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	3D-RISM	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	gain	_	_	VB	_	_	_	_	_
27	deep	_	_	JJ	_	_	_	_	_
28	insights	_	_	NNS	_	_	_	_	_
29	into	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	binding	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	cyclic	_	_	JJ	_	_	_	_	_
35	peptide	_	_	NN	_	_	_	_	_
36	at	_	_	IN	_	_	_	_	_
37	DPP4	_	_	NNP	_	_	_	_	_
38	druggable	_	_	JJ	_	_	_	_	_
39	region	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	Finally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	fluorescence	_	_	NN	_	_	_	_	_
4	assay	_	_	NN	_	_	_	_	_
5	was	_	_	VBD	_	_	_	_	_
6	used	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	demonstrate	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	potential	_	_	JJ	_	_	_	_	_
11	role	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	oxytocin	_	_	NN	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	DPP4	_	_	NN	_	_	_	_	_
17	inhibitor	_	_	NN	_	_	_	_	_
18	experimentally	_	_	RB	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_

